Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02066532 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Dawn L. HershmanOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT02598557 | Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 2 | Aug 22, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT02637024 | Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation(OPAR) | completed | Phase 2 | 280 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03193853 | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 12 | Joyce O'ShaughnessyOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00255788 | Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 49 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00258375 | OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 15 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01138384 | Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 19 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01147484 | A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer(IND197) | completed | Phase 2 | 47 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01656538 | A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | completed | Phase 2 | 81 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03018080 | Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer(PePPy) | completed | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT00146562 | Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | completed | Phase 2 | 135 | Harold J. Burstein, MD, PhDOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT03454529 | The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer | completed | Phase 2 | 24 | Michael SimonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03464942 | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer(AZTEC) | completed | Phase 2 | 54 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT01124695 | Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer | completed | Phase 2 | 124 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Jun 29, 2023 | clinicaltrials |
| NCT00244933 | Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer | completed | Phase 2 | 19 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00879086 | A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer | completed | Phase 2 | 104 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01269346 | Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer | completed | Phase 2 | 52 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01439282 | Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer | completed | Phase 2 | 77 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05159778 | Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) | completed | Phase 2 | 26 | HiberCell, Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003236 | Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02673398 | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | completed | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00579826 | Study of Breast Cancer Prevention by Letrozole in High Risk Women | completed | Phase 2 | 55 | Carol Fabian, MDOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03872791 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05727098 | Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy. | completed | Phase 2 / Phase 3 | 75 | National Cancer Institute, EgyptOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00002826 | Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 36 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 7, 2023 | clinicaltrials |
| NCT02768701 | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT00921115 | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | completed | Phase 2 | 42 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT02526498 | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery(TRIUMPH-T) | completed | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT03988036 | A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)(Keyriched-1) | completed | Phase 2 | 46 | Women's Cancer Study Group GmbHOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT04752059 | Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases(TUXEDO-1) | completed | Phase 2 | 15 | Medical University of ViennaOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT02408770 | Breast Cancer - Anti-Progestin Prevention Study 1(BC-APPS1) | completed | Phase 2 | 24 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | May 6, 2023 | clinicaltrials |
| NCT02891759 | Compare Outcomes Between Two Acellular Dermal Matrices | completed | Phase 2 | 320 | Washington University School of MedicineOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03321929 | Intraoperative Detection of Residual Cancer in Breast Cancer | completed | Phase 2 | 234 | Lumicell, Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00337649 | A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 27 | Hoffmann-La RocheINDUSTRY | 1 | Apr 28, 2023 | clinicaltrials |
| NCT00881361 | Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer | completed | Phase 2 | 756 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT01417286 | Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer | completed | Phase 2 | 69 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01922921 | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | completed | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05812326 | PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 15 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT03564171 | Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer | completed | Phase 2 / Phase 3 | 63 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04836520 | SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. | completed | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT00258960 | Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | completed | Phase 2 | 49 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT00432172 | Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | completed | Phase 2 | 189 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03025880 | Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC(PANGEA) | completed | Phase 2 | 36 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 24, 2023source: clinicaltrials